Last edition
News about "Gene Therapy for Peripheral Arterial Disease Moves"
AnGes and Boehringer Ingelheim Advance PAD Gene Therapy with New Manufacturing Deal
Boehringer Ingelheim has signed a contract development and manufacturing agreement with AnGes Inc. for the drug substance of AnGes’ investigational therapy for peripheral arterial disease (PAD). This agreement marks a key step following AnGes’ recent completion of clinical trials and its plan to submit a biologics license application (BLA).
Gene Therapy For Peripheral Arterial Disease Moves | 21/08/2025 | By Darshana | 178
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy